Acarbose
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Acarbose: Drug Repurposing Evaluation Report
One-Sentence Summary
Acarbose is an alpha-glucosidase inhibitor commonly used worldwide for the management of Type 2 Diabetes Mellitus. The TxGNN model has not generated any predicted new indications for this drug at this time. Combined with significant data gaps in mechanism of action, safety data, and the absence of Taiwan market authorisation, this candidate currently lacks sufficient basis for a repurposing evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no Taiwan licence data; internationally known for Type 2 Diabetes Mellitus) |
| Predicted New Indication | None — no TxGNN predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No predictions or supporting studies) |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data is not available in the evidence pack. Based on general pharmacological knowledge, Acarbose is an alpha-glucosidase inhibitor that works in the small intestine by reversibly inhibiting alpha-glucosidase enzymes, thereby delaying the digestion of complex carbohydrates and reducing postprandial blood glucose elevations. It is widely approved internationally for the treatment of Type 2 Diabetes Mellitus.
However, the TxGNN model has not generated any predicted new indications for Acarbose at this time. Without a predicted indication, it is not possible to evaluate the mechanistic plausibility of a repurposing hypothesis. This may be due to insufficient knowledge graph connectivity for this drug, or the model may not have identified disease associations that meet its confidence threshold.
Before any repurposing assessment can proceed, the following foundational data must be obtained: (1) formal MOA documentation from DrugBank, (2) Taiwan TFDA regulatory and package insert information, and (3) a valid TxGNN prediction output.
Clinical Trial Evidence
Currently no predicted indication has been generated by TxGNN; therefore, no targeted clinical trial search was conducted.
Literature Evidence
Currently no predicted indication has been generated by TxGNN; therefore, no targeted literature search was conducted.
Taiwan Market Information
Acarbose has no active marketing authorisations in Taiwan. Zero licences were returned from the TFDA query (queried 2026-03-29).
Safety Considerations
Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, and drug–drug interactions) returned as data gaps or not found in current queries.
Data Gaps Summary
The following critical data gaps were identified and must be resolved before this candidate can be re-evaluated:
| Gap ID | Category | Item | Severity | Impact | Remediation |
|---|---|---|---|---|---|
| DG001 | Drug Level | TFDA Package Insert Warnings/Contraindications | Blocking | Cannot enter Stage 1 safety screening | Download and parse package insert PDF from TFDA website |
| DG002 | Drug Level | Mechanism of Action (MOA) | High | Affects mechanistic relevance analysis | Query DrugBank API |
Conclusion and Next Steps
Decision: Hold
Rationale: Acarbose currently has no TxGNN-predicted new indications, no Taiwan market authorisation, and critical data gaps in both safety and mechanism of action. There is no repurposing hypothesis to evaluate at this time.
To proceed, the following is needed:
- Obtain a valid TxGNN prediction output for Acarbose (re-run the model or verify knowledge graph coverage for DB00284)
- Resolve DG001 (Blocking): Retrieve TFDA package insert warnings and contraindications
- Resolve DG002 (High): Obtain detailed MOA data from DrugBank API
- Confirm Taiwan regulatory pathway — if the drug has never been marketed in Taiwan, evaluate whether an international comparator product dossier could support a repurposing application
- Once a predicted indication is available, conduct targeted clinical trial and literature searches to establish evidence level
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.